Urol. praxi. 2023;24(2):58-63 | DOI: 10.36290/uro.2023.040

Intravesical thermochemotherapy - indication, patient preparation and practical aspects of administration

doc. MUDr. Michal Fedorko, Ph.D., FEBU1, 2, MUDr. Alena Sorokač Kubolková1, 2, MUDr. Jakub Papirek1, MUDr. Vítězslav Vít1, 2
1 Urologická klinika FN Brno
2 Lékařská fakulta Masarykovy univerzity, Brno

Device-assisted intravesical chemotherapy aims to increase the efficacy of intravesical chemotherapy in the treatment of non-muscle-invasive bladder cancer. Currently, its use is limited to cases where radical cystectomy cannot be performed after failure (or intolerance or unavailability) of intravesical immunotherapy with BCG vaccine, either because of poor performance status of the patient or because of refusal of surgery. In the Czech Republic, two methods of this treatment based on the use of thermal energy are available. The article provides summary of both these methods with an emphasis on practical aspects of their use.

Keywords: chemotherapy, intravesical, bladder cancer, radiofrequency, termochemotherapy, chemohypertermia.

Accepted: June 13, 2023; Published: June 15, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fedorko M, Sorokač Kubolková A, Papirek J, Vít V. Intravesical thermochemotherapy - indication, patient preparation and practical aspects of administration. Urol. praxi. 2023;24(2):58-63. doi: 10.36290/uro.2023.040.
Download citation

References

  1. Babjuk M, Burger M, Compérat E, et al. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). In: EAU Guidelines. Edn. presented at the EAU Annual Congres Amsterdam 2022. Arhhem, The Netherlands: EAU Guidelines Office; 2022:1-58.
  2. Brausi M, Oddens J, Sylvester R, Bono A, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65(1):69-76. Go to original source... Go to PubMed...
  3. Pang KH, Noon AP. Selection of patients and benefit of immediate radical cystectomy for non-muscle invasive bladder cancer. Transl Androl Urol. 2019; 8(1):101-107. Go to original source... Go to PubMed...
  4. Horňák J, Brisuda A, Babjuk M. Selhání intravezikální BCG imunoterapie v terapii svalovinu neinvadujících nádorů močového měchýře - současnost a budoucnost léčby. Rozhl Chir. 2022;101(3):108-113. Go to PubMed...
  5. Hendricksen K. Device-assisted intravesical therapy for non-muscle invasive bladder cancer. Transl Androl Urol. 2019;8(1):94-100. Go to original source... Go to PubMed...
  6. Brisuda A. Nové možnosti intravezikální instilační terapie u karcinomu močového měchýře. Ces Urol. 2018;22(4):251-256.
  7. Kuncová J. Intravezikální, radiofrekvencí indukovaná chemohypertermie v léčbě svalovinu neinfiltrujících nádorů močového měchýře. Ces Urol. 2022;26(3):174-185.
  8. Melgarejo-Segura MT, Morales-Martínez A, Yáñez-Castillo Y, et al. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer. Urol Oncol. 2022, doi: 10.1016/j.urolonc.2022.09.016. Online ahead of print. Go to original source... Go to PubMed...
  9. Tan WP, Chang A, Brousell SC, et al. Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study. Int J Hyperthermia. 2020;37(1):854-860. Go to original source... Go to PubMed...
  10. Seznam zdravotních výkonů. Registrační list - 76532 [online]. Praha: ÚZIS ČR, © 2016 [cit. 31-1-2023]. Available from: http://szv.mzcr.cz/Vykon/Detail/76532.
  11. Plata A, Guerrero-Ramos F, Garcia C, González-Díaz A, et al. Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain. J Clin Med. 2021;10(21):5105. Go to original source... Go to PubMed...
  12. Angulo JC, Álvarez-Ossorio JL, Domínguez JL, et al. Hyper­thermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2022, doi: 10.1016/j.euo.2022.10.008. Online ahead of print. Go to original source... Go to PubMed...
  13. Tan WS, Prendergast A, Ackerman C, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. 2022. doi: 10.1016/j.eururo.2022.08.003. Online ahead of print. Go to original source... Go to PubMed...
  14. Guerrero-Ramos F, González-Padilla DA, et al. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol. 2022;40(4):999-1004. Go to original source... Go to PubMed...
  15. Pijpers OM, Hendricksen K, Mostafid H, et al. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urol Oncol. 2022;40(2):62. Go to original source... Go to PubMed...
  16. Stemberger A, Tan WP, Bello AP, et al. A multicenter study of 2-year outcomes following hyperthermia therapy with Mitomycin C in treating BCG unresponsive non-muscle invasive bladder cancer: recirculant hyperthermic intravesical chemotherapy. J Urol. 2022;207(5):E932. Go to original source...
  17. van Valenberg H, Colombo R, Witjes F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32(4):351-362. Go to original source... Go to PubMed...
  18. Seznam zdravotních výkonů. Registrační list - 76534 [online]. Praha: ÚZIS ČR, © 2016 [cit. 31-1-2023]. Available from: http://szv.mzcr.cz/Vykony/Detail/76534.
  19. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003; 21(23):4270-4276. Go to original source... Go to PubMed...
  20. Colombo R, Salonia A, Leib Z, et al. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011; 107(6):912-918. Go to original source... Go to PubMed...
  21. Arends TJ, Nativ O, Maffezzini M, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol. 2016;69(6):1046-1052. Go to original source... Go to PubMed...
  22. Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. Eur Urol. 2019;75(1):63-71. Go to original source... Go to PubMed...
  23. Witjes JA. Radiofrequency-induced Thermochemotherapy for Recurrent Non-muscle-invasive Bladder Cancer: A New Treatment for an Unmet Need? Eur Urol. 2019;75(1):72-73. Go to original source... Go to PubMed...
  24. Brummelhuis ISG, Wimper Y, Witjes-van Os HGJM, et al. Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer. Cancers. 2021;13(3):377. Go to original source... Go to PubMed...
  25. Babjuk M. Re: Long-term Experience with Radiofrequency-induced Hyperthermia Combined with Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer. Eur Urol. 2022;81(5):541. Go to original source... Go to PubMed...
  26. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2011;60(1):81-93. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.